VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Karsh Discusses Treatment Sequencing in mCRPC

Lawrence Karsh, MD
Published: Friday, May 17, 2013

Lawrence Karsh, MD, director of the Clinical Research Department, at The Urology Center of Colorado, discusses strategies for sequencing the wide array of new agents available to treat men with castration-resistant prostate cancer.

Given the overall lack of data on sequencing, Karsh recommends utilizing practical considerations to determine how to best treat patients. These parameters include patient preference, comorbidities, and financial considerations. Furthermore, he notes, with the overall lack of available guidelines and biomarkers, most patients will likely receive several of the approved therapies.

Lawrence Karsh, MD, director of the Clinical Research Department, at The Urology Center of Colorado, discusses strategies for sequencing the wide array of new agents available to treat men with castration-resistant prostate cancer.

Given the overall lack of data on sequencing, Karsh recommends utilizing practical considerations to determine how to best treat patients. These parameters include patient preference, comorbidities, and financial considerations. Furthermore, he notes, with the overall lack of available guidelines and biomarkers, most patients will likely receive several of the approved therapies.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x